Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax, Cladribine, and Cytarabine Followed by Allo-HSCT for R/R AML
NCT07757672Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- Apr 2029
01
Overview
A Phase 2 trial of sonrotoclax in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07757672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757672.